Cargando…

Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort

OBJECTIVE: Long-term efficacy of metformin in polycystic ovarian syndrome (PCOS) apart from in those with impaired glucose tolerance or diabetes remains unproven. We aimed to evaluate the impact of metformin in overweight-obese patients with PCOS and normal baseline glycemic homeostasis. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensterle, Mojca, Kravos, Nika Aleksandra, Ferjan, Simona, Goricar, Katja, Dolzan, Vita, Janez, Andrej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993269/
https://www.ncbi.nlm.nih.gov/pubmed/31829964
http://dx.doi.org/10.1530/EC-19-0449
_version_ 1783492995446734848
author Jensterle, Mojca
Kravos, Nika Aleksandra
Ferjan, Simona
Goricar, Katja
Dolzan, Vita
Janez, Andrej
author_facet Jensterle, Mojca
Kravos, Nika Aleksandra
Ferjan, Simona
Goricar, Katja
Dolzan, Vita
Janez, Andrej
author_sort Jensterle, Mojca
collection PubMed
description OBJECTIVE: Long-term efficacy of metformin in polycystic ovarian syndrome (PCOS) apart from in those with impaired glucose tolerance or diabetes remains unproven. We aimed to evaluate the impact of metformin in overweight-obese patients with PCOS and normal baseline glycemic homeostasis. METHODS: A 10-year longitudinal follow-up of a retrospective cohort comprising 159 patients with PCOS defined by Rotterdam criteria, BMI ≥25 kg/m(2) and normal initial glucose homeostasis (age 28.4 ± 6.4 years, BMI 34.9 ± 6.6 kg/m(2)) that had been receiving metformin 1000 mg BID. Collection data contained 6085 time-points including anthropometric, hormonal and metabolic parameters. RESULTS: After the first year body mass (BM) decreased for 3.9 ± 6.8 kg (P < 0.001) and remained stable during the following 3 years. Menstrual frequency (MF) increased to 3.0 ± 3.9 bleeds/year (P < 0.001) after first year to over 11 bleeds/year in the following years. The total testosterone and androstenedione decreased to 15.4 ± 47.9% and 11.3 ± 46.4% within first year, with further decrease in total testosterone and androstenedione to 37.8 ± 61.8 and 24.8 ± 40.5% at the fifth year of the follow-up. The total conversion rate to prediabetes and diabetes was extremely low throughout observation period. Less than 25% of patients continued with metformin for more than 5 years with further dropout to only 6% on metformin therapy at the tenth year of follow-up. CONCLUSIONS: Long-term metformin treatment of overweight-obese women with PCOS and normal baseline glycemic homeostasis resulted in reduction and stabilization of BM, improvements of MF and androgen profile and low conversion rate to diabetes.
format Online
Article
Text
id pubmed-6993269
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-69932692020-02-03 Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort Jensterle, Mojca Kravos, Nika Aleksandra Ferjan, Simona Goricar, Katja Dolzan, Vita Janez, Andrej Endocr Connect Research OBJECTIVE: Long-term efficacy of metformin in polycystic ovarian syndrome (PCOS) apart from in those with impaired glucose tolerance or diabetes remains unproven. We aimed to evaluate the impact of metformin in overweight-obese patients with PCOS and normal baseline glycemic homeostasis. METHODS: A 10-year longitudinal follow-up of a retrospective cohort comprising 159 patients with PCOS defined by Rotterdam criteria, BMI ≥25 kg/m(2) and normal initial glucose homeostasis (age 28.4 ± 6.4 years, BMI 34.9 ± 6.6 kg/m(2)) that had been receiving metformin 1000 mg BID. Collection data contained 6085 time-points including anthropometric, hormonal and metabolic parameters. RESULTS: After the first year body mass (BM) decreased for 3.9 ± 6.8 kg (P < 0.001) and remained stable during the following 3 years. Menstrual frequency (MF) increased to 3.0 ± 3.9 bleeds/year (P < 0.001) after first year to over 11 bleeds/year in the following years. The total testosterone and androstenedione decreased to 15.4 ± 47.9% and 11.3 ± 46.4% within first year, with further decrease in total testosterone and androstenedione to 37.8 ± 61.8 and 24.8 ± 40.5% at the fifth year of the follow-up. The total conversion rate to prediabetes and diabetes was extremely low throughout observation period. Less than 25% of patients continued with metformin for more than 5 years with further dropout to only 6% on metformin therapy at the tenth year of follow-up. CONCLUSIONS: Long-term metformin treatment of overweight-obese women with PCOS and normal baseline glycemic homeostasis resulted in reduction and stabilization of BM, improvements of MF and androgen profile and low conversion rate to diabetes. Bioscientifica Ltd 2019-12-11 /pmc/articles/PMC6993269/ /pubmed/31829964 http://dx.doi.org/10.1530/EC-19-0449 Text en © 2020 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
Jensterle, Mojca
Kravos, Nika Aleksandra
Ferjan, Simona
Goricar, Katja
Dolzan, Vita
Janez, Andrej
Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort
title Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort
title_full Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort
title_fullStr Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort
title_full_unstemmed Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort
title_short Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort
title_sort long-term efficacy of metformin in overweight-obese pcos: longitudinal follow-up of retrospective cohort
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993269/
https://www.ncbi.nlm.nih.gov/pubmed/31829964
http://dx.doi.org/10.1530/EC-19-0449
work_keys_str_mv AT jensterlemojca longtermefficacyofmetformininoverweightobesepcoslongitudinalfollowupofretrospectivecohort
AT kravosnikaaleksandra longtermefficacyofmetformininoverweightobesepcoslongitudinalfollowupofretrospectivecohort
AT ferjansimona longtermefficacyofmetformininoverweightobesepcoslongitudinalfollowupofretrospectivecohort
AT goricarkatja longtermefficacyofmetformininoverweightobesepcoslongitudinalfollowupofretrospectivecohort
AT dolzanvita longtermefficacyofmetformininoverweightobesepcoslongitudinalfollowupofretrospectivecohort
AT janezandrej longtermefficacyofmetformininoverweightobesepcoslongitudinalfollowupofretrospectivecohort